IDO1 and myalgic encephalomeyelitis/chronic fatigue syndrome: Therefore, increases in kynurenine and its metabolites resulting from increased IDO activity could contribute to neuroinflammation, increased glutamate, altered immune system, depression, altered gut microbiota, and fatigue in ME/CFS patients [366, 367, 369].